<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00292929</url>
  </required_header>
  <id_info>
    <org_study_id>WRAIR 1128</org_study_id>
    <secondary_id>USUHS G183RW</secondary_id>
    <secondary_id>HSRRB A-13276</secondary_id>
    <nct_id>NCT00292929</nct_id>
  </id_info>
  <brief_title>Study of the Safety of Intravenous Artesunate</brief_title>
  <official_title>A Phase 1 Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Single Intravenous Doses of Artesunate Administered to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the safety, tolerability and pharmacokinetics of a
      single dose of the antimalarial drug artesunate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Malaria</condition>
  <condition>Malaria, Cerebral</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous artesunate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males and non-pregnant, non-lactating females

          -  Have a normal ECG that may include benign PAC's and PVC's, 1st degree AV block, 2nd
             degree AV block, Wenckebach

          -  Have a normal blood pressure (BP) and heart rate (HR). These will be measured after
             resting supine for about 3 minutes. Normal BP is defined as less than 140 mm Hg
             systolic and less than 90 mm Hg diastolic. Normal baseline HR is 50 to 90 bpm without
             symptoms.

          -  Body mass index between 18 and 29 kg/m**2 or, if out of range, not clinically
             significant (within 15% of their ideal body weight).

          -  Be able to verbalize understanding of the consent form, provide written informed
             consent and verbalize willingness to complete study procedures

          -  Have a brief physical examination that demonstrates no clinically significant
             contraindication for participating in the study.

          -  If female, have a negative serum pregnancy test at screening and urine pregnancy at
             admission or be postmenopausal, had a hysterectomy, been sterilized, or agrees to
             practice effective contraception for the duration fo the study and for a period of 12
             weeks after stopping study drug.

        Exclusion Criteria:

          -  Have received any investigational drug or vaccine in the period 0 to 16 weeks before
             entry to the study.

          -  Have been on a liquid protein diet in the last year

          -  Have any clinically significant abnormal physical findings at the screening
             examination

          -  Have any clinically significant abnormalities in the results of laboratory screening
             evaluation

          -  Have used any prescription drugs within 14 days prior to admission or non-prescription
             drugs (including herbals or dietary supplements) within 7 days prior to admission

          -  Existence of any surgical or medical condition that, in the judgement of the clinical
             investigator, might interfere with the distribution, metabolism or excretion of the
             drug

          -  Presence of history of drug allergy requiring treatment. Hay fever is allowed unless
             it is active or has required treatment within the previous 2 months

          -  Donation or loss of greater than 400 ml of blood in the period 0 to 12 weeks before
             entry to the study.

          -  Serious adverse reaction or hypersensitivity to any drug, particularly artemisinins

          -  CAGE (screening test for alcoholism) positive (2 out of 4 criteria) or has a history
             of recent alcohol abuse

          -  Use of illicit drugs

          -  Family history of sudden cardiac death or prolonged QT syndrome (defined as 500 msec
             noted in repeat tracings)

          -  History of seizure, syncope, or trouble with hearing or balance or other neurological
             disorder

          -  History of severe psychiatric disorder or hospitalization for severe psychiatric
             disorder

          -  Current job or personal habit of reversed sleep-wake cycle

          -  History of cardiac disease to include cardiomyopathy, valvular disease, arrhythmia,
             ischemia, or enlarged heart

          -  Presence of hepatitis B surface antigen (Hbs-Ag), hepatitis C antibody (antiHCV) or
             HIV type 1 at screening

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J Weina, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Walter Reed Army Institute of Research (WRAIR)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uniformed Services University of the Health Sciences</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814-4799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2006</study_first_submitted>
  <study_first_submitted_qc>February 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2006</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <keyword>artesunate</keyword>
  <keyword>artemisinin</keyword>
  <keyword>falciparum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Cerebral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 5, 2017</submitted>
    <returned>June 20, 2017</returned>
    <submitted>June 27, 2017</submitted>
    <returned>January 26, 2018</returned>
    <submitted>February 1, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

